CAS 931399-19-8

GSK360A

Kontrolliertes Produkt

CAS: 931399-19-8

Applications GSK360A orally active HIF-PHD inhibitor. GSK360A exerts systemic and local effects by stabilizing HIF-1α signaling and improves long-term ventricular function, remodeling, and vascularity in a model of established ventricular dysfunction. These findings suggest that GSK360A may be suitable for the treatment of post-MI remodeling and heart failure.
References Bao, W.-K. et al.: J. Cardio. Pharmacol., 56, 147 (2010);

Formel: C₁₇H₁₇FN₂O₅

Farbe und Form: Neat

Molekulargewicht: 348.33

Ref: TR-G797600

GSK 360A

CAS: 931399-19-8

Inhibitor of prolyl 4-hydroxylase PHD

Formel: C₁₇H₁₇FN₂O₅

Reinheit: Min. 95%

Farbe und Form: Powder

Molekulargewicht: 348.33 g/mol

Ref: 3D-FG23706

GSK360A

CAS: 931399-19-8

GSK360A is a novel prolyl hydroxylase (PHD) domain-containing enzyme inhibitor.

Formel: C₁₇H₁₇FN₂O₅

Reinheit: 98%

Farbe und Form: Solid

Molekulargewicht: 348.33

Ref: TM-T27476